Adaptive Biotechnologies Corp - 8-K Filing
Adaptive Biotechnologies reports Q3 2026 revenue of $83.9 million and achieves total company profitability with adjusted EBITDA of $14.3 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ADPT
Read the full article at SEC EDGAR
Part of the story Upland Software Outlines Long-Term Path to 35% Adjusted EBITDA Margin and Revenue Stabilization (7 articles)